-
Azilsartan Medoxomil: Evidence From a 2024 Meta-Analysis
2026-09-05
This systematic review and meta-analysis integrated efficacy and safety evidence from 11 randomized controlled trials of azilsartan medoxomil in hypertension. The findings support dose-related blood pressure reduction without a broad increase in adverse events, while the small diabetes subgroup and limited clinical scope require cautious interpretation.
-
PPM-18: Reliable iNOS Assay Design
2026-09-04
This scenario-driven guide explains how SKU C4074, PPM-18 (N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide), can improve interpretation of viability, proliferation, and inflammatory-response assays. It connects mechanism, solvent compatibility, dose selection, orthogonal readouts, and vendor-quality checks for reproducible inflammation and sepsis research.
-
Ranolazine Workflows for Ischemia Research
2026-09-04
Ranolazine supports paired electrophysiology and metabolism experiments by combining late sodium current inhibition with glucose oxidation enhancement. This guide shows how to apply it in cardiac ischemia research while carefully extending metabolic assays into HBV-related liver models without confusing exploratory observations with antiviral evidence.
-
Marein and ABCG2: Restoring Chemosensitivity
2026-09-03
The reference study identifies marein, a chalcone-type flavonoid from Coreopsis tinctoria Nutt, as a competitive inhibitor of the ABCG2 drug efflux transporter. By increasing intracellular exposure to ABCG2-substrate chemotherapeutics and restoring drug sensitivity in resistant cancer cells, the work provides a mechanistic framework for studying transporter-mediated multidrug resistance.
-
Tetracycline Hydrochloride: Translation as Strategy
2026-09-03
Tetracycline Hydrochloride offers translational researchers a mechanistically defined way to interrogate bacterial protein synthesis, Staphylococcus aureus susceptibility, and skin microbiome modulation. This article connects ribosomal inhibition with practical assay design while using rapid ROS-based platinum therapeutics as a carefully bounded contrast rather than an unsupported indication.
-
Deferasirox Fe3+ Chelate: Assay Design
2026-09-02
Deferasirox Fe3+ chelate supports rigorous iron overload treatment research when investigators distinguish preformed ferric complex chemistry from free-ligand pharmacology. This guide translates clinical pharmacokinetic insight into practical assay controls, solubility decisions, and interpretation strategies.
-
Oltipraz: From Nrf2 Biology to MASLD Translation
2026-09-02
Oltipraz offers translational researchers a defined small-molecule entry point into Nrf2-driven phase II defense, with potential value for connecting chemoprevention research to MASLD mechanisms. This article interprets recent evidence linking Nrf2, autophagy, and ferroptosis while outlining a rigorous workflow for separating pathway activation from downstream liver-protection claims.
-
L1023 Anti-Cancer Compound Library Workflow
2026-09-01
Build mechanism-aware cancer screens around 1,164 curated bioactive compounds, from pathway triage to migration and target-validation assays. L1023 combines pre-dissolved DMSO stocks with a practical workflow for comparing phenotypic hits against BRAF, mTOR, apoptosis, and other oncogenic programs.
-
Preeclampsia UCMSCs: Senescence and Cytoskeletal Dysfunction
2026-09-01
The reference study identifies cellular senescence, mitochondrial impairment, and cytoskeletal instability as interconnected abnormalities in umbilical cord mesenchymal stem cells derived from preeclamptic pregnancies. By combining donor-group phenotyping, EdU-based proliferation analysis, transcriptomics, imaging, and dasatinib–quercetin treatment, it provides a mechanistic framework for evaluating how the preeclamptic microenvironment alters UCMSC function.
-
Praeruptorin A Blocks NF-κB in Poly(I:C) Macrophages
2026-08-31
The reference study shows that praeruptorin A suppresses poly(I:C)-induced inflammatory activation in RAW264.7 macrophages, with RNA sequencing linking its effects to inflammatory signaling and validation by molecular assays. Its main contribution is to extend evidence for praeruptorin A beyond lipopolysaccharide models while defining a practical in vitro framework for studying TLR3-associated macrophage inflammation.
-
Caffeic Acid Phenethyl Ester for NF-κB Assays
2026-08-31
Caffeic Acid Phenethyl Ester (CAPE) enables pathway-focused testing of NF-κB in inflammation, neurodegeneration, and tumor biology. This workflow shows how to pair CAPE with zebrafish imaging, cytokine measurements, and angiogenesis-related endpoints while controlling for solubility, timing, and pathway crosstalk.
-
EdU Imaging Kits (488) for HCC Proliferation
2026-08-30
EdU Imaging Kits (488) convert transient DNA replication into a sensitive fluorescence readout for cancer cell-cycle studies. This guide connects HAUS1-focused hepatocellular carcinoma research with practical imaging and flow cytometry workflows, including assay design, controls, and troubleshooting.
-
Phosphatase Inhibitor Cocktail 1: Signal Fidelity
2026-08-29
Phosphatase Inhibitor Cocktail 1 supports phosphorylation state preservation from tissue lysis through Western blotting and phosphoproteomic analysis. This guide connects inhibitor selection with tissue-specific assay design, using UPF3A research to explain why pre-analytical control matters.
-
ARCA Cy3 EGFP mRNA: A Better Delivery Assay
2026-08-28
ARCA Cy3 EGFP mRNA (5-moUTP) enables researchers to separate cellular uptake, endosomal escape, and translation in one experimentally coherent workflow. This article explains how to use its Cy3 and EGFP signals to diagnose delivery bottlenecks, informed by recent endosomal-disruption research.
-
EdU Imaging Kits (488) for CRC Proliferation
2026-08-28
EdU Imaging Kits (488) turn transient S-phase activity into a quantitative fluorescence readout without the DNA denaturation required by BrdU assays. The workflow is especially useful for testing circEIF2S2 perturbation, rescue experiments, and tumor–T-cell co-cultures in colorectal cancer models.